MAP2K1 G276W
|
Melanoma
|
MAP2K1 G276W
|
Melanoma
|
vemurafenib Sensitive: C3 – Early Trials
|
vemurafenib Sensitive: C3 – Early Trials
|
MAP2K1 G276W
|
Melanoma
|
MAP2K1 G276W
|
Melanoma
|
dabrafenib Sensitive: C3 – Early Trials
|
dabrafenib Sensitive: C3 – Early Trials
|